Cardio Diagnostics Holdings (CDIO) EBIT (2021 - 2026)

Cardio Diagnostics Holdings has disclosed EBIT across 6 years of filings, most recently posting -$1.5 million for Q2 2026.

• In Q2 2026, EBIT rose 10.76% year-over-year to -$1.5 million; the TTM figure through Jun 2026 stood at -$6.5 million (down 3.58% YoY), while the FY2025 annual figure was -$6.5 million, up 22.49% from the prior year.
• EBIT came in at -$1.5 million for Q2 2026 at Cardio Diagnostics Holdings, up from -$1.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$227094.0 in Q1 2022 to a low of -$4.2 million in Q1 2024.
• Average EBIT over 5 years is -$1.7 million, with a median of -$1.5 million recorded in 2023.
• Year-over-year, EBIT slumped 198127.71% in 2022 and surged 60.79% in 2025.
• Over 5 years, EBIT stood at -$2.4 million in 2022, then jumped by 35.16% to -$1.5 million in 2023, then rose by 1.66% to -$1.5 million in 2024, then increased by 3.51% to -$1.5 million in 2025, then declined by 2.39% to -$1.5 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$1.5 million in Q2 2026, -$1.8 million in Q1 2026, and -$1.5 million in Q4 2025.